Quanterix Corporation

QTRX - Financial Snapshot

Healthcare sector | Medical Devices industry

View on:
Ranks:

Metrics for QTRX

Price $3.37
Shares Outstanding 47.06M
All-Time Low $4.05
52-Week Low $4.05

Balance Statement Metrics

Net Cash / Share $0
cashValuePerShare = (Cash + Short Term Investments - Total Liabilities) / Shares Outstanding
⇒ cashValuePerShare = ((118,232,000 - 123,036,000) / 47,064,985) = -0.1021
Net Current Assets / Share $1.9
netCurrentAssetsPerShare = (Current Assets - Total Liabilities) / Shares Outstanding
⇒ netCurrentAssetsPerShare = ((212,257,000 - 123,036,000) / 47,064,985) = 1.8957
Net Tangible Assets / Share $2.92
netTangibleAssetsPerShare = (Total Assets - Intangibles - Total Liabilities) / Shares Outstanding
⇒ netTangibleAssetsPerShare = ((418,766,000 - 158,163,000 - 123,036,000) / 47,064,985) = 2.92
Avg CA Burn (Quarterly %) -9.01% (as of 5-5-2026)

Earning Metrics

Max Earning Power / Share $-2.95
maxEarningPowerPerShare = (EBITDA / EP_MULTIPLIER) / Shares Outstanding
⇒ maxEarningPowerPerShare = ((-14,561,000 / 0.105) / 47,064,985) = -2.9465
Adjusted Earning Power $-4.68
adjustedEarningPower = (Net Income / EP_MULTIPLIER) / Shares Outstanding
⇒ adjustedEarningPower = ((-23,117,000 / 0.105) / 47,064,985) = -4.6778
Non-Cash Charges to Market Cap 5.87%
nonCashChargeToMKTCAP = Non-Cash Charges / Market Capitalization
Data as of: Price 05-04-26 16:00 ET, Balance Sheet 2025-12-31, Income Statement 2025-12-31, Cash Flow 2025-12-31

Indicators

Dividend indicators Value Date
Current Dividend Streak No 5-5-2026
Consecutive Years Paid No 5-5-2026
Pays Dividend No 5-5-2026
Income indicators Value Date
Current Dividend Streak No 5-5-2026
EBITDA Positive No 5-5-2026
Net Income Positive No 5-5-2026

Metric History Explorer

Pick a metric to view its history table and chart.

Tangible Book Value Per Share History

Formula: Tangible Book Value / shares from balance statements. Includes 2 quarterly.

Chart plots one TBV / Share point per report date (duplicate same-date annual/quarterly rows are merged).

Report Date Period TBV / Share Tangible Book Value Shares Used
2025-12-31 Quarterly $2.94 137.6M ($137,567,000) 46.7M (46,744,000)
2025-09-30 Quarterly $3.34 155.9M ($155,926,000) 46.7M (46,683,000)

Dividend Payments

Historical cash dividends per share from Yahoo ex-dividend dates.

Date Dividend / Share
No dividend payment history available yet

Shares Outstanding Changes

Date Shares Outstanding Delta
2026-04-28 47,064,985 +125,010
2026-03-10 46,939,975 +229,178

Short Interest Changes

Latest short-interest change: 4,304,442 shares (9.72% of float) | Days to cover: 4.66

Date Short Interest Delta Δ %
2026-04-27 4,304,442 shares -10,695 -0.25%
2026-04-17 4,315,137 shares +212,446 +5.18%
2026-03-24 4,102,691 shares -14,988 -0.36%
2026-03-12 4,117,679 shares +209,681 +5.37%

Interesting Volume Days

Volume/ratio use shares outstanding as of the event date (frozen).

Date Volume Shares Outstanding Volume / Shares Price
No interesting volume events

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications. It also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company's products include assays include all components required to run enzyme-based immunoassay, such as beads, capture and detector reagents, and enzyme reagents and substrate; and replacement parts, reagents, and antibodies. In addition, the company offers contract research services, including sample testing, homebrew assay development, custom assay development, lucent diagnostic, and LDT testing services. The company primarily operates in the areas of neurology, oncology and immunology, and inflammation. It sells its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct field sale, support organizations, and distributors or sales agents. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Billerica, Massachusetts.